Nanopath is developing a first-in-class in vitro diagnostics platform to transform how diseases are diagnosed. We aim to replace lengthy molecular testing workflows by bringing rapid, high-quality diagnostics closer to the patient. Our mission is to improve patient outcomes – starting with women – through a purpose-built platform that delivers actionable results within a single office visit.

The company is headquartered at The Engine, the premier tough technology incubator in the Kendall Square ecosystem. We are collectively committed to health equity and the design of solutions for underserved populations and low-resource settings. Corporate sustainability – both environmental and social – is at the forefront of our decision making.

About the Role

Nanopath is seeking a Process Development Senior Research Associate / Associate Scientist to join our Assay R&D team and help develop, optimize, and scale the workflows that support Nanopath’s diagnostic platform. This role will be highly hands-on and will support process development across assay preparation, reagent development, and analytical testing.

Responsibilities

Support development of robust, repeatable protocols for reagent manufacturing, array fabrication, and assay execution.
Assist with process characterization, QC, stability, reproducibility, and verification-supporting studies as Nanopath advances toward regulated product development.
Prepare reagents, samples, and materials; maintain lab organization; and support routine equipment use and maintenance.
Collect, analyze, summarize, and present experimental data in a clear and timely manner.
Troubleshoot experimental workflows and collaborate with assay, engineering, product, and operations team members to identify root causes and implement improvements.

Qualifications

Bachelor’s or Master’s degree in bioengineering, biomedical engineering, molecular biology, chemistry, or a related field with 4+ years of relevant industry experience.
Experience with liquid handler automation, automated assay workflows, or programming / operating automated laboratory platforms.
Experience with nucleic acid assays, biosensors, microarrays, or spotting / printing technologies
Familiarity with design control, quality systems, GLP/GxP principles, or documentation practices for regulated diagnostics.
Extremely well-organized, with a high level of efficiency, attention to detail, and motivation for completing tasks accurately and on time.
Excellent communication and presentation skills.
Experience in cross-functional and highly collaborative work environments.
Passionate about Nanopath’s mission for developing a purpose-built solution for women’s health.

Don’t meet every single requirement? Studies have shown that women and people of color are less likely to apply to jobs unless they meet every single qualification. At Nanopath we are dedicated to building a diverse and inclusive workplace, so if you’re excited about this role but your past experience doesn’t align perfectly with every point in the job description, we encourage you to apply anyways. You may be just the right candidate for this or other roles!

Nanopath Inc. is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law.

Nanopath does not accept unsolicited resumes from recruiters or agencies and we will not be responsible for any fees related to resumes that are unsolicited. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Nanopath, and Nanopath will not owe any referral or other fees with respect thereto.

About the company

Nanopath develops a molecular diagnostics platform geared toward women’s health. The system tests patient samples for viral, bacterial, and fungal pathogens without nucleic acid amplification, delivering actionable results during a single office visit. Its emphasis on women’s health, a no-amplification workflow, and roots as a Dartmouth spin-off distinguish it from general diagnostic firms by focusing on on-site, routine screening for female patients. The company aims to become the standard go-to point-of-care system for routine women's health screening, empowering clinicians and patients with rapid, accurate information.

Company Size

11-50

Company Stage

Grant

Total Funding

$14.5M

Headquarters

Cambridge, Massachusetts

Founded

2019

Get referred to Nanopath

See people who can refer or advise you

Simplify's Take

What believers are saying

Nanopath raised over $20 million after its 2022 Series A and later grants.
Massachusetts Life Sciences Center support in 2026 advanced validation using nearly 1,000,000 biospecimens.
Nanopath expanded from 13 to 20 employees during 2025, signaling execution momentum.

What critics are saying

Nanopath still lacks FDA marketing authorization, so revenue depends on future clearance.
Complicated-UTI diagnostics face Abbott, BD, and bioMérieux, all defending entrenched lab channels.
If clinical validation stalls, investors fund a platform without sales, threatening shutdown by 2027.

What makes Nanopath unique

Nanopath’s November 2025 FDA Breakthrough designation covers rapid complicated-UTI pathogen and resistance testing.
Its amplification-free platform targets 15-minute point-of-care results, unlike centralized molecular labs.
October 2025 leadership hires added clinical, manufacturing, and commercialization veterans across five roles.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
Wellness Program
Mental Health Support
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

NewZiana

Sep 26th, 2026

LSU students win US$10,000 in innovation challenge.

LSU students win US$10,000 in innovation challenge. New ziana > local news > LSU students win US$10,000 in innovation challenge. Staff Reporter BULAWAYO - Two Lupane State University (LSU) students have won US$10,000 after their agricultural technology start-up topped the Emerging Technology Category of the Old Mutual Zimbabwe Mutual Value Creation Challenge. Stream History Documentaries Mark Rukanda and Leona Nyoni, founders of NanoPath, beat more than 1,100 entries to secure the prize, placing student innovation and technology-driven solutions at the centre of efforts to address challenges affecting Zimbabwe's agricultural sector. NanoPath, which operates under Nannovoe Private Limited, is developing FreshGuard, a nano-enabled edible coating sprayed onto fresh produce to extend shelf life and reduce post-harvest losses. The innovation targets produce such as tomatoes, potatoes, bananas, and selected vegetables, aiming to reduce spoilage while preserving the quality and marketability of agricultural products. Rukanda and Nyoni established the venture after receiving grant funding from the Zimbabwe Agricultural Development Trust (ZADT) through its CAUSEWAY Project Student Incubation Initiative. Their success comes as Zimbabwe continues to promote innovation, entrepreneurship, and technology development among students and young people as part of efforts to develop solutions to challenges facing various sectors of the economy. The FreshGuard innovation has the potential to support farmers, traders, and consumers by reducing losses between harvesting and the point of sale, particularly for highly perishable agricultural products. The achievement also highlights the growing role of universities in nurturing student-led enterprises that develop practical solutions with commercial and social value. For LSU, the award further recognises the institution's students as emerging innovators capable of turning research and ideas into products and businesses. The Ministry of Higher and Tertiary Education, Innovation, Science, and Technology Development has been encouraging institutions of higher learning to strengthen innovation, entrepreneurship, and technology development as the country seeks to build a knowledge-based economy. The US$10,000 prize is expected to provide NanoPath with additional resources as the students continue developing and commercialising FreshGuard. The achievement by Rukanda and Nyoni also demonstrates the impact of student incubation programs and financial support in transforming university-based ideas into potentially viable enterprises.

Massachusetts Government

Aug 17th, 2026

MassVentures Announces $4.5 Million in Grant Funding to Help 26 Massachusetts Startups Grow and Create Jobs

START grants help companies turn cutting-edge research into new products, businesses and jobs in Massachusetts

Massachusetts Life Sciences Center

Apr 28th, 2026

Brigham and Women's Hospital's Crimson Core advances Nanopath's women's health diagnostics platform.

Brigham and Women's Hospital's Crimson Core advances Nanopath's women's health diagnostics platform. * April 28, 2026 The Massachusetts Life Sciences Center (MLSC) is proud to support shared research infrastructure that strengthens discovery, collaboration, and commercialization across the Commonwealth. One example is the Crimson Core at Brigham and Women's Hospital (BWH), led by Drs. Lynn Bry and Georg Gerber, which received $3.3 million in 2022 through the MLSC's Research Infrastructure program. This investment supported a critical resource available to researchers across Massachusetts, providing high-quality biofluid samples and specialized processing services that advance research studies, clinical trials, and translational science through the purchase of computational hardware, an Oxford Nanopore sequencer, updated gnotobiotic mouse equipment, and Bruker NMR probes. Since receiving MLSC support, the Crimson Core has handled nearly 1,000,000 biospecimens, with more than 700,000 released to enable research, demonstrating the scale and statewide impact of this shared scientific infrastructure. The impact extends beyond academia and into commercialization. For an early-stage company like Nanopath, this access was transformational. Nanopath, a 2023 awardee of the MLSC's Massachusetts Next Generation (MassNextGen) Initiative, is a Series A-stage diagnostics company rethinking how diagnostic testing is delivered in clinical settings by delivering actionable molecular results within a single office visit. The company is currently pioneering a novel platform for women's health designed to enable faster test results to improve the diagnosis of infectious diseases where speed and accuracy are critical. Through resources provided by the Crimson Core, Nanopath was able to advance development of its diagnostic platform by accessing hundreds of well-characterized patient biospecimens and the expertise needed to better understand gold-standard diagnostic workflows. This work helped the company generate critical validation data and refine how its technology could integrate into real-world clinical practice. "We were immersed in academic research environment, connected with leading clinicians at BWH, and exposed to state-of-the-art diagnostic technology," said Drs. Alison Burklund and Amogha Tadimety, Nanopath. "The first time we walked into the lab, we were in awe of the capabilities." The ability to work with fresh clinical samples, avoid the cost barriers of commercial biobanks, and collaborate directly within the academic and clinical environment at BWH accelerated both technical validation and strategic decision-making. This helped Nanopath generate key data for the company's research and refine their strategy on how its technology could integrate into existing clinical practices Since engaging with the Crimson Core, Nanopath has raised more than $20 million in follow-on funding and received FDA Breakthrough Device Designation for its diagnostic targeting complicated urinary tract infections. Additionally, the company has received non-dilutive funding and business strategy coaching from industry experts through the MassNextGen Initiative, along with support through the MLSC's Internship Challenge, which has enabled the hiring of 10 interns since 2022. Together, MLSC-supported research infrastructure and programming for early-stage companies has driven Nanopath's development momentum, underscoring the role of shared resources like the Crimson Core in translating scientific innovation into real-world impact for patients and enabling faster transitions from discovery to impact. Success Stories Featured in The Beat

Femtech Insider

May 22nd, 2024

Nanopath Secures $4M in Federal Grants to Advance Women’s Health Diagnostics

Nanopath, a point-of-care diagnostics company, has received $4 million in federal grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF). This funding is intended to support the development of...

FinSMEs

May 21st, 2024

Nanopath Receives $4M in Grants

Nanopath receives $4M in grants.

Nanopath

Process Development Senior Research Associate

About the job